维罗纳制药美股盘前涨超20%

Group 1 - Verona Pharmaceuticals' stock surged over 20% in pre-market trading following reports of Merck agreeing to acquire the company at a price of $107 per ADS, valuing the total transaction at approximately $10 billion [1] - The pre-market trading volume for Verona Pharmaceuticals reached 332,500 shares, with a pre-market price of $104.230, reflecting a 20% increase from the previous closing price of $91.200 [2] - The highest pre-market price recorded was $104.680, indicating strong investor interest and market activity surrounding the acquisition news [2] Group 2 - The total market capitalization of Verona Pharmaceuticals is approximately $7.395 billion, with a total share count of 85.132 million [2] - The stock has shown significant volatility, with a 52-week high of $99.010 and a low of $18.510, highlighting the potential for substantial price movements in response to market events [2] - The acquisition by Merck is expected to enhance Verona's market position and could lead to further developments in its product pipeline [1]